211 related articles for article (PubMed ID: 37651273)
21. Aducanumab: Appropriate Use Recommendations.
Cummings J; Aisen P; Apostolova LG; Atri A; Salloway S; Weiner M
J Prev Alzheimers Dis; 2021; 8(4):398-410. PubMed ID: 34585212
[TBL] [Abstract][Full Text] [Related]
22. A Time-to-Event Exposure-Response Model for Amyloid-Related Imaging Abnormalities Following Administration of Aducanumab to Subjects With Early Alzheimer Disease.
Muralidharan KK; Karumanchi S; Kowalski KG; Burkett P; Chapel S; Rajagovindan R; Nestorov I
J Clin Pharmacol; 2022 Aug; 62(8):1030-1046. PubMed ID: 35285968
[TBL] [Abstract][Full Text] [Related]
23. MR imaging features of amyloid-related imaging abnormalities.
Barakos J; Sperling R; Salloway S; Jack C; Gass A; Fiebach JB; Tampieri D; Melançon D; Miaux Y; Rippon G; Black R; Lu Y; Brashear HR; Arrighi HM; Morris KA; Grundman M
AJNR Am J Neuroradiol; 2013 Oct; 34(10):1958-65. PubMed ID: 23578674
[TBL] [Abstract][Full Text] [Related]
24. The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study.
Martens RM; Bechten A; Ingala S; van Schijndel RA; Machado VB; de Jong MC; Sanchez E; Purcell D; Arrighi MH; Brashear RH; Wattjes MP; Barkhof F
Eur Radiol; 2018 Mar; 28(3):1215-1226. PubMed ID: 28956123
[TBL] [Abstract][Full Text] [Related]
25. Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval.
Howe MD; Britton KJ; Joyce HE; Pappas GJ; Faust MA; Dawson BC; Riddle MC; Salloway SP
J Prev Alzheimers Dis; 2023; 10(4):765-770. PubMed ID: 37874098
[TBL] [Abstract][Full Text] [Related]
26. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications.
Doran SJ; Sawyer RP
Front Neurosci; 2024; 18():1326784. PubMed ID: 38312931
[TBL] [Abstract][Full Text] [Related]
27. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients.
Ketter N; Brashear HR; Bogert J; Di J; Miaux Y; Gass A; Purcell DD; Barkhof F; Arrighi HM
J Alzheimers Dis; 2017; 57(2):557-573. PubMed ID: 28269765
[TBL] [Abstract][Full Text] [Related]
28. Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease.
Vitek GE; Decourt B; Sabbagh MN
Expert Opin Investig Drugs; 2023 Feb; 32(2):89-94. PubMed ID: 36749830
[TBL] [Abstract][Full Text] [Related]
29. Lecanemab: Appropriate Use Recommendations.
Cummings J; Apostolova L; Rabinovici GD; Atri A; Aisen P; Greenberg S; Hendrix S; Selkoe D; Weiner M; Petersen RC; Salloway S
J Prev Alzheimers Dis; 2023; 10(3):362-377. PubMed ID: 37357276
[TBL] [Abstract][Full Text] [Related]
30. Alzheimer disease neuropathology in a patient previously treated with aducanumab.
Plowey ED; Bussiere T; Rajagovindan R; Sebalusky J; Hamann S; von Hehn C; Castrillo-Viguera C; Sandrock A; Budd Haeberlein S; van Dyck CH; Huttner A
Acta Neuropathol; 2022 Jul; 144(1):143-153. PubMed ID: 35581440
[TBL] [Abstract][Full Text] [Related]
31. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.
Liu E; Wang D; Sperling R; Salloway S; Fox NC; Blennow K; Scheltens P; Schmidt ME; Streffer J; Novak G; Einstein S; Booth K; Ketter N; Brashear HR;
Neurology; 2018 Mar; 90(10):e877-e886. PubMed ID: 29429971
[TBL] [Abstract][Full Text] [Related]
32. Aducanumab: Appropriate Use Recommendations Update.
Cummings J; Rabinovici GD; Atri A; Aisen P; Apostolova LG; Hendrix S; Sabbagh M; Selkoe D; Weiner M; Salloway S
J Prev Alzheimers Dis; 2022; 9(2):221-230. PubMed ID: 35542993
[TBL] [Abstract][Full Text] [Related]
33. Validation of 3- and 5-point severity scales to assess ARIA-E.
Bracoud L; Klein G; Lyons M; Scelsi MA; Wojtowicz J; Bullain S; Purcell D; Fiebach JB; Barakos J; Suhy J
Alzheimers Dement (Amst); 2023; 15(4):e12503. PubMed ID: 38026755
[TBL] [Abstract][Full Text] [Related]
34. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
Villain N; Planche V; Levy R
Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
[TBL] [Abstract][Full Text] [Related]
35. Monitoring Blood-Brain Barrier Integrity Following Amyloid-β Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model.
Blockx I; Einstein S; Guns PJ; Van Audekerke J; Guglielmetti C; Zago W; Roose D; Verhoye M; Van der Linden A; Bard F
J Alzheimers Dis; 2016 Sep; 54(2):723-35. PubMed ID: 27567811
[TBL] [Abstract][Full Text] [Related]
36. Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease.
Joseph-Mathurin N; Llibre-Guerra JJ; Li Y; McCullough AA; Hofmann C; Wojtowicz J; Park E; Wang G; Preboske GM; Wang Q; Gordon BA; Chen CD; Flores S; Aggarwal NT; Berman SB; Bird TD; Black SE; Borowski B; Brooks WS; Chhatwal JP; Clarnette R; Cruchaga C; Fagan AM; Farlow M; Fox NC; Gauthier S; Hassenstab J; Hobbs DA; Holdridge KC; Honig LS; Hornbeck RC; Hsiung GR; Jack CR; Jimenez-Velazquez IZ; Jucker M; Klein G; Levin J; Mancini M; Masellis M; McKay NS; Mummery CJ; Ringman JM; Shimada H; Snider BJ; Suzuki K; Wallon D; Xiong C; Yaari R; McDade E; Perrin RJ; Bateman RJ; Salloway SP; Benzinger TLS; Clifford DB;
Ann Neurol; 2022 Nov; 92(5):729-744. PubMed ID: 36151869
[TBL] [Abstract][Full Text] [Related]
37. Vascular Considerations for Amyloid Immunotherapy.
Foley KE; Wilcock DM
Curr Neurol Neurosci Rep; 2022 Nov; 22(11):709-719. PubMed ID: 36269539
[TBL] [Abstract][Full Text] [Related]
38. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
Wang D; Kowalewski EK; Koch G
Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
[TBL] [Abstract][Full Text] [Related]
39. Commentary: Aducanumab-Related ARIA: Paean or Lament?
Wassef HR; Colletti PM
Clin Nucl Med; 2022 Aug; 47(8):707-709. PubMed ID: 35543641
[TBL] [Abstract][Full Text] [Related]
40. Amyloid-Related Imaging Abnormalities in an Aged Squirrel Monkey with Cerebral Amyloid Angiopathy.
Heuer E; Jacobs J; Du R; Wang S; Keifer OP; Cintron AF; Dooyema J; Meng Y; Zhang X; Walker LC
J Alzheimers Dis; 2017; 57(2):519-530. PubMed ID: 28269776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
